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Abstract: Trastuzumab, a humanized mouse monoclonal antibody directed against HER2 (Human Epidermal Growth Factor Receptor 2), 
is currently a keystone in the treatment of breast cancer. Meanwhile, trastuzumab has been validated for use in other types of cancer 
too. But the data on HER2 expression in colorectal cancer are ambiguous, with reported overexpression of HER2 varying between zero 
and 84%. In this review these studies are evaluated and compared. It shows that many factors influence the determination of HER2-
expression, especially of the intracellular fraction of HER2. It is concluded that although membranous overexpression of HER2 is low 
in colorectal cancer with only 5% of all patients being positive, a significant proportion of the patients (30%) shows cytoplasmic HER2 
overexpression. The clinical impact of enhanced intracellular HER2 is not known, because the nature and origin have not completely 
been revealed yet. Enlightening this process could be a stepping stone towards targeting of intracellular HER2 as a treatment option.
Keywords: HER2, ErbB2, Her2/neu, colorectal cancer, survival, membranous, cytoplasmic, immunohistochemistry, tissue microarray, 
biomarker, trastuzumab, herceptin
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Background
Colorectal cancer is a major worldwide health 
problem with an annual incidence of 1.2 million 
and an annual mortality of over 600,000 people.1,2 
One of the reasons for the relatively high mortal-
ity is high tumor stage at the time of diagnosis, 
caused by the lack of symptoms or the presence 
of aspecific symptoms during the initial stages of 
disease. With an increase in tumor stage, the risk 
of recurrence after resection rises and the chances 
of survival deteriorate. Chemotherapy has shown 
to be an efficient strategy for adjuvant therapy, 
but is still not capable of preventing recurrence in 
all patients.3 Therefore there is numerous ongoing 
research for alternative compounds to be used as 
adjuvant therapy. Monoclonal antibodies and other 
biologicals, targeting tumor-associated proteins 
and blocking essential processes of the tumor, are 
extensively studied. A crucial step in this process 
is the identification of tumor specific proteins that 
can be targeted by these compounds. One of these 
targets is HER2, which is primarily associated with 
breast cancer. This review provides an overview of 
all accessible studies that reported on HER2 over-
expression in colorectal cancer, focusing especially 
on the differences between these studies.
HeR2
Over the last two decades, the transmembrane 
tyrosine kinase receptor Human Epidermal Growth 
Factor Receptor 2 (HER2, also known as HER2/
neu, ErbB2 or p185) has been shown to be an 
effective target for adjuvant therapy for especially 
breast cancer. HER2 is found to be upregulated in 
20%–30% of all breast cancers. The 40–100 fold pro-
tein upregulation is due to a genetic amplification to 
25–50 copies.4 Slamon et al showed that tumors with 
overexpression of HER2 are more aggressive and, 
consequently, these patients have a worse prognosis 
compared to patients with HER2-negative tumors.5,6 
Trastuzumab (Herceptin®), a monoclonal antibody 
against the extracellular domain of HER2, showed a 
dramatic improvement in survival as well as recur-
rence rate when used as adjuvant therapy after breast 
cancer surgery. The recurrence risk dropped by 40% 
and the mortality rate by 30%.7,8 This novel HER2-
targeted therapy required a standardized scoring of 
immunohistochemical HER2 tumor staining to select 
the breast cancer patients that could benefit from 
trastuzumab. The scoring of HER2-status comprises 
four different outcomes: 0 (no staining or staining 
in ,10% of the tumor cells), 1+ (a faint or incom-
plete membrane staining in .10% of the tumor cells), 
2+ (a weak to moderate complete membrane stain-
ing in .10% of the tumor cells) and 3+ (an intense 
and complete membrane staining in .30% of the 
tumor cells).9 There are multiple immunohistochemi-
cal kits available for HER2-staining, but the poly-
clonal antibody-based Herceptest (Dako, Glostrup, 
Denmark), which has been approved by the FDA 
(US Food and Drug Administration), is mostly used. 
Remarkably, it is reported that monoclonal antibody-
based kits have a better agreement with HER2 gene 
amplification, as determined by FISH (fluorescence 
in situ hybridization).10,11 Generally, the 3+ cases 
have an excellent concordance with FISH, while the 
2+ results are more equivocal.12 Current guidelines 
demand a FISH-analysis to determine the gene ampli-
fication in 2+ cases.13
Colorectal HeR2 expression
After the breakthrough in breast cancer, HER2 has 
been evaluated as a target in other tumor types. After 
a 37% improvement in overall survival, this recently 
led to FDA-approval for the use of trastuzumab in 
HER2-positive metastatic gastric cancer.14
Several studies evaluating HER2 in colorectal 
cancer resulted in a large debate at the end of the 
last century because overexpression rates varied 
between zero and 84%.15 Also the clinical signifi-
cance of HER2 in these publications was not con-
sistent, with some publications associating HER2 
overexpression to survival,16–18 while others failed 
to find such a correlation.19–21 Most researchers 
agreed that the differences in expression were likely 
due to differences in technical approaches, anti-
bodies, and scoring protocols, but conclusive data 
were never presented. Since then a large number of 
immunohistochemical studies have emerged about 
HER2 in colorectal cancer. The majority showed 
membranous overexpression rates between zero 
and 15%.22–31 Remarkably, some studies reported 
both membranous and cytoplasmic overexpres-
sion with much higher rates up to 60%.32–38 Up to 
now, there is no consistency about the proportion of 
HER2-overexpression in colorectal tumors.
HeR2 overexpression in colorectal cancer
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Immunohistochemical  
detection of HeR2
The major difficulty in comparing immunohistochem-
ical studies is the variety in antibodies. Additionally, 
differences in technical procedures such as tissue fixa-
tion, slide storage procedures, antigen retrieval, and 
incubation time could influence the staining outcome. 
The type of HER2-antibody used varied widely in the 
27 analyzed studies in this review. In total, 15 differ-
ent types of antibodies were reported, eight monoclo-
nals and seven polyclonals (Table 1). The claim of 
Arnaout et al in an early study that polyclonal anti-
bodies mainly stain cytoplasmic HER2, in contrast to 
monoclonal antibodies staining primarily membranous 
HER2, was not confirmed in more recent publications.41 
For example, Half et al observed a cytoplasmic stain-
ing in 64% of the cases using monoclonal antibod-
ies CB11 and 3B5.23 Furthermore, there is evidence 
that some antibodies might not be completely spe-
cific for HER2, which could result in aberrant stain-
ing patterns. Schrohl et al showed that monoclonal 
antibody clones 4B5 and CB11 (respectively from 
PATHWAY®; Ventana Medical Systems Inc, Tucson, 
AZ, USA and Oracle®; Leica Microsystems GmbH, 
Wetzlar, Germany) cross-reacted with HER4. The 
antibodies used in the much used Herceptest, did not 
cross-react with any other HER-receptors.47
Although differences in antigen specificity are pre-
sumably the main cause for the differences between 
various reports, some studies using the same antibody 
still obtained varying results. For example, antibody 
NCL-CB11 (Novocastra Laboratories, Newcas-
tle Upon Tyne, UK) is used in 5 different studies 
with a reported overexpression rate between 22% 
and 82%. Therefore, procedural variations might 
also substantially contribute to the variations found 
Table 1. An overview of the antibodies used in the 27 studies analyzing HeR2 overexpression in colorectal cancer. The 
antibodies are organized based on the scoring categories of their publications: studies that split into membranous overex-
pression and cytoplasmic overexpression (A), and studies without distinction between the overexpressing regions (B).
(A) Membrane and cytoplasm HeR2 expression evaluated independently








4D541 Genentech Monoclonal 70 0.00 0.00
HeR1441 Genentech Polyclonal 70 0.00 34.29
21N41,42 Polyclonal 93 1.08 5.38
NCL-CB1116,22,26 Novocastra Monoclonal 310 2.58 30.97
No name18,29 Nichirei Polyclonal 390 2.82 24.87
e2-400123 Neomarkers Monoclonal 96 5.21 63.54
3B523 Oncogene 
science
Monoclonal 96 5.21 63.54
Herceptest25,27,28,30,31 Dako Polyclonal 857 7.47
4B524 ventana Monoclonal 106 10.38
CB1143 Biogenex Monoclonal 86 13.95
Z488136 Zymed Polyclonal 137 47.45
A048534 Dako Polyclonal 74 51.35






e2-400138 Neomarkers Monoclonal 85 36.47
Unknown20 Triton Polyclonal 32 37.50
A048533,35 Dako Polyclonal 310 47.42
NCL-CB1121,44 Novocastra Monoclonal 541 49.91
300G-937 Digiesi et al Monoclonal 22 59.09
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in immunohistochemical HER2 studies. Incubation 
times of the antibodies in the various studies ranged 
from 60 minutes to overnight, and the antibody 
dilutions were between 1:20 and 1:250.16,21,22,26,44 
However, these variations do not entirely explain the 
differences in HER2 staining as no consistent cor-
relation is observed between incubation time and 
overexpression. Both Kountourakis et al and Sun et al 
report an overexpression of approximately 22% 
(cytoplasmic and membranous); Kountourakis et al 
used 1:250 dilution and 60 minutes incubation, while 
Sun et al used 1:40 with an overnight incubation.21,26 
The two studies reported a highest overexpression of 
approximately 82%, incubation times of respectively 
45 minutes and overnight respectively were used. In 
these studies, however, the comparability is ham-
pered by the use of different antibodies.45,46 We per-
formed a comparison of incubation times in our own 
laboratory, incubating paraffin-embedded colorectal 
tumor tissue using A0485, an anti-HER2 polyclonal 
antibody (DAKO Glostrup, Denmark) after antigen 
retrieval. As shown in Figure 1, an incubation time 
longer than the 30 minutes indicated in the manufac-
turer’s protocol for breast cancer tissues gives rise 
to a stronger cytoplasmic staining pattern, allow-
ing better comparison between different colorectal 
tumors. Because the absolute amount of stainable 
HER2 in colorectal cancers seems low when com-
pared to breast cancer, it seems advisable for immu-
nohistochemical analysis of HER2-overexpression 
to adapt the protocols for breast cancer for use in col-
orectal cancer.
Mirlacher et al showed a dramatic decrease in stain-
ing intensity for HER2 in tissue microarrays (TMAs) 
between freshly cut and stored slides.39 We confirmed 
these results recently using our own TMA consisting of 
500 colorectal cancer tissue samples obtained between 
1991 and 2001. This TMA was produced using the 
same techniques as described earlier by our group for 
breast cancer.40 Slides were incubated with A0485. 
The operation date, and therefore the length of storage 
time, had a great impact particularly on cytoplasmic 
HER2 expression. In the group of patients operated on 
before 1996, 8.4% showed overexpression of cytoplas-
mic HER2, while in the group of patients operated on 
in or after 1996, 42.7% expressed cytoplasmic over-
expression. Tumors from patients operated on in 1998 
or later showed the highest percentage of cytoplasmic 
staining (52%, manuscript in preparation). Therefore, 
it is likely that in studies having a long period of tissue 
collection the HER2 overexpression rate is underes-
timated especially in the older samples, which could 
partly explain the variation between studies.
These data emphasize the importance of standard-
ized staining procedures, as relatively insignificant 
procedure variations might lead to completely dif-
ferent staining patterns and thereby different overex-
pression rates.
scoring procedure
A number of publications analyzed HER2- 
overexpression in colorectal tumors with genomic 
techniques like FISH, RT-PCR, Southern blotting, and 
Northern blotting. Kavanagh et al performed FISH 
on two 3+ cases and on nine 2+ cases. Both 3+ cases 
were confirmed to have gene amplification, but only 
one 2+ case was confirmed.24 Nathanson et al found 
approximately the same results, confirming three out 
of three 3+ cases and one out of two 2+ cases with 
both FISH and PCR.28 Ooi et al confirmed all 3+ and 
2+ cases with FISH.29 Together these results confirmed 
that for colorectal cancers, the observations are similar 
for those found in breast cancer, ie, that 3+ overexpres-
sion is conclusive for gene amplification, whereas 2+ 
staining is equivocal for gene amplification, and likely 
has other mechanisms of genetic overexpression.
When analyzing all accessible papers about 




Figure 1. Paraffin-embedded colorectal cancer tissue was incubated 
with A0485 anti-HeR2 antibody with increasing incubation times of 
30 minutes, 1 hour, 2 hours and overnight.
note: with longer incubation times, an increase in cytoplasmic staining 
(brown) can be observed.
HeR2 overexpression in colorectal cancer
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scoring methods, it was observed that most publica-
tions follow the breast cancer protocol by examining 
only membranous overexpression,24,25,27–31,34,36,42,43 or 
split their scoring in membranous and cytoplasmic 
overexpression.16,18,22,23,26,41 In general, the mem-
branous overexpression rates varied between 0% 
and 15%. Only Knösel et al and Park et al reported 
membranous overexpression of over 40%.34,36 
However, Park et al only confirmed two out of 27 
3+ cases with FISH, which puts their results in a dif-
ferent perspective. Without these two outliers, the 
weighted average overexpression of membranous 
HER2 was 5%. For cytoplasmic overexpression 
however, the rates varied between 0% and 66%, with 
a weighted average of 30% (Table 2).
A number of publications did not split their 
scores into membranous and cytoplasmic over-
expression, but took them together to determine 
positivity.20,21,32,33,35,37,38,45,46 The observed overexpression 
rates varied between 22% and 83%, with a weighted 
average of 50% (Table 2). Unfortunately, no conclu-
sions can be drawn about this percentage regarding the 
fraction of membranous or cytoplasmic overexpression. 
Based on the publications that used split results, it is 
Table 2. An overview of all papers reporting about HeR2 overexpression in colorectal cancer. The papers are organized 
based on the scoring categories: split into membranous overexpression and cytoplasmic overexpression (A), or papers with-
out distinguishing between the overexpressing regions (B). The weighted average was calculated with and without outliers. 
when one paper used more than one antibody, all antibodies were examined separately for the weighted average.
(A) Membraneous and cytoplasmic HeR2 overexpression evaluated separately
Authors Year Antibody patients (n) % membrane % cytoplasm
Kay et al16 1994 NCL-CB11 164 0 34
Arnaout et al41 1992 4D5, 21N, HeR14 70 0 7–34
Kim et al25 2004 Herceptest 185 1
Osako et al18 1998 Nichirei 146 2 66
Nathanson et al28 2003 Herceptest 169 3
Ooi et al29 2004 Nichirei 244 3
Schuell et al30 2006 Herceptest 77 4
McCann et al42 1990 21N 23 4
Half et al23 2004 e2-4001 and 3B5 96 5 64
Ochs et al31 2004 Herceptest 109 6
Kountourakis et al26 2006 NCL-CB11 106 6 17
Gill et al22 2011 NCL-CB11 40 8 58
Kavanagh et al24 2009 4B5 106 10
Dursun et al43 2001 CB11 86 14
Li et al27 2011 Herceptest 317 15
Park et al36 2007 Z4881 137 47*
Knosel et al34 2002 A0485 74 51*
Total % positive membrane 9.22
Total % positive membrane without outliers (*) 5.38
Total % positive cytoplasm 30.58
(B) Membrane and cytoplasm evaluated together
Authors Year Antibody patients (n) % positive staining
Sun et al21 1995 NCL-CB11 293 23
Demirbas et al32 2005 CB11 124 36
Uner et al38 2005 e2-4001 85 36
Kluftinger et al20 1992 Triton 32 38
Kruszewski et al35 2010 A0485 202 47
Jesus et al33 2005 A0485 108 48
Porcelli et al37 2001 300G-9 22 59
McKay et al44 2002 NCL-CB11 248 82
Kapitanovic et al45 1997 3B5 and CB11 176 82
Maurer et al46 1998 NCL-CBe1 35 83
Total % positive staining 55.76
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expected that the majority of overexpression in these 
publications is located in the cytoplasm, and only a 
minor fraction is overexpressed in the membrane.
Overall, it can be concluded that about 5% of col-
orectal tumors have membranous overexpression of 
HER2, while the cytoplasmic overexpression varies 
strongly with an average around 30%. However, it 
is likely that this value is an underestimation due to 
the loss of HER2 antigen in older tissue samples as 
described earlier.
cytoplasmic HeR2
The FDA-approved scoring system for breast cancer is 
based entirely on membranous HER-2 overexpression. 
Cytoplasmic overexpression in breast cancer occurs, 
but there are strict guidelines to ignore this.48,49 
These guidelines are very specific as trastuzumab 
is only capable of binding the extracellular domain 
of membranous HER2. In other words, cytoplasmic 
HER2 would not have any consequence for clinical 
decisions about therapy. For years cytoplasmic 
overexpression of HER2 has been regarded as not 
relevant for breast cancer. Intracellular HER2 cannot 
be targeted by trastuzumab, it does not correlate with 
HER2 mRNA levels,51 it does not correlate to any 
clinical outcome,52 and it may even be a different 
protein than membranous HER2.
In contrast to breast cancer, there is evidence that 
in colorectal cancer cytoplasmic HER2 could in fact 
be associated with survival prognosis. Of 15 publi-
cations that analyzed clinical prognostic parameters, 
six showed a worse patient survival with cytoplasmic 
tumor overexpression of HER2.16,18,22,32,34,45 Seven 
studies showed no correlation with any clinical 
parameter.20,21,26,33,35,44,46 Two other papers described 
a positive correlation between cytoplasmic overex-
pression and well-differentiated tumors.23,38 Both 
publications hypothesize that enhanced cytoplasmic 
HER2 is an early marker in colorectal cancer, but 
decreases with progressing tumor stage and tumor 
dedifferentiation. This seems contradictory to the 
findings that patients with a HER2-cytoplasmic over-
expressing tumor have a decreased survival rate as 
patients with progressed tumor (higher stage, dedif-
ferentiation) would have less HER2 expression, but 
poorer prognosis. Moreover, one publication showed 
a worse differentiation and more lymph node metas-
tases in cytoplasmic HER2-overexpressing tumors.32
When combining the distinction in scoring methods 
within those studies that report a clinical correlation, 
a remarkable pattern becomes clear. Of all seven 
studies that report a lack of clinical correlation, six of 
them do not split their scoring into membranous and 
cytoplasmic staining.20,21,33,35,44,46 In contrast, out of 
the six studies that report a clinical correlation, four 
of them do split their results in membranous and cyto-
plasmic staining.16,18,22,34 Although this has never been 
confirmed in a large multi-center trial, these studies 
strongly suggest a clinical relevance of cytoplasmic 
HER2 overexpression in colorectal cancer.
Assuming that cytoplasmic HER2 has a prognostic 
role in colorectal cancer, it might also be involved in 
tumor pathogenesis like membranous HER2 in breast 
cancer. A plausible explanation would be that cyto-
plasmic HER2 is forming homodimers, leading to an 
intracellular activation of the tyrosine kinase domain. 
Administration of trastuzumab will therefore not 
have any effect, as this antibody targets the extracel-
lular domain only. Lapatinib, an intracellular tyrosine 
kinase inhibitor, has recently been approved for 
treatment of HER2-positive breast cancer patients.50 
If cytoplasmic HER2 is indeed actively involved 
in colorectal carcinogenesis the administration of 
lapatinib, or other intracellular HER2-targeting com-
pounds, could be a breakthrough in the treatment of 
especially this type of cancer.
Biology of cytoplasmic HeR2
In breast cancer, it was suggested that cytoplasmic 
HER2 is a truncated or different protein, based on the 
fact that a 155 kD peptide was found, in contrast to 
the 185 kD HER2 found on the membrane. However, 
for colorectal cancer there have been ambiguous 
observations. Osako et al performed a western blot 
analysis on one membranous overexpressing speci-
men, five membranous cytoplasmic specimens, and 
one negative sample. They observed 185 kD and 
155 kD peptides in the membranous overexpressing 
specimen, but only 155 kD peptides in the cytoplas-
mic overexpressing specimens.18 On the other hand, 
Kapitanovic et al performed a study in which they 
were able to split the cell lysate into a cytoplasmic 
and membranous fraction, and performed a western 
blot analysis with a different anti-HER2 antibody than 
Osako et al. They observed a 185 kD peptide in both 
fractions, and reported no 155 kD peptide. A western 
HeR2 overexpression in colorectal cancer
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blot using a P-Tyr antibody, detecting phosphorylated 
(activated) tyrosine kinase domains showed a 185 kD 
peptide in the intracellular fraction, indicating an 
intracellular activated HER2-receptor.45 This would 
suggest that the activated HER2 was internalized 
upon activation, or that HER2 was activated intracel-
lularly eg, via homodimerization. Half et al analyzed 
the localization of cytoplasmic HER2 in colorectal 
cancer by electron microscopy after labeling with an 
anti-HER2 antibody and a secondary colloidal gold-
labeled antibody. HER2 was located in the rough 
endoplasmatic reticulum (rER), consistent with newly 
synthesized peptides. It was also detected in cytosolic 
vacuoles, at the plasma membrane, and at desmosomes 
in the intercellular junctions. Particularly because of 
the localization at the rER, it is likely that this HER2 
is derived from original peptide synthesis, and thus 
would be of genomic origin. Most likely, however, 
HER2 internalization and synthesis are occurring at 
the same time. Until these experiments are repeated 
using an antibody which has been validated to be 
solely specific for HER2, the origin of cytoplasmic 
HER2 will not be clarified.
Based on the hypothesis that cytoplasmic HER2 in 
colorectal cancer is actually newly synthesized rather 
than internalized, three different studies analyzed 
genomic amplification to determine the genomic 
background of HER2-overexpression. Half et al 
discovered membranous overexpression in only 
five out of 96 colorectal tumors (5%), while they 
determined cytoplasmic overexpression in 61 tumors 
(63%). Four out of five membranous HER2-
overexpressing tumors showed amplification with 
FISH, while no cytoplasmic HER2-overexpressing 
tumors were confirmed with this technique. Moreover, 
RT-PCR was performed and showed a 12-fold higher 
mRNA expression in membranous overexpressing 
tumors compared to cytoplasmic overexpressing 
tumors.23 Pavlakis et al performed FISH-analysis 
on all cases described by Kountourakis et al. All 3+ 
cases of membranous overexpression were confirmed 
as being amplified, while only one of three 2+ cases 
was confirmed. No single cytoplasmic overexpressing 
tumor was confirmed.26,54 These results clearly indicate 
that membranous overexpression is associated with 
gene amplification, while cytoplasmic overexpression 
is due to other mechanisms. Maurer et al performed 
a northern blot and a Southern blot on the 29 cases 
overexpressing HER2, without a distinction between 
membranous and cytoplasmic overexpression. 
Presumably this concerns cytoplasmic HER2 
based on the high percentage of positive tumors 
(82%). They observed a 1.5 fold increase in mRNA 
via northern blot in tumors compared to healthy 
tissue, but the Southern blot did not show any gene 
amplification.46 Again, this indicates that cytoplasmic 
HER2 overexpression is based on mechanisms other 
than gene amplification.
For other types of cancer, it has been shown 
that overexpression of HER2 can also occur via 
mechanisms other than gene amplification, eg, via 
increased levels of promoter-binding proteins as 
was observed by Kameda et al in gastric cancer. 
He observed elevated levels of binding proteins to 
the TATA-box located in the promoter-region of the 
HER2-gene, which led to overexpression of HER2.55 
Theoretically, mutations in downstream targets of 
HER2, for example KRAS, might also influence the 
expression of HER2 via affected feedback processes. 
These mechanisms could play a role in the observed 
cytoplasmic HER2 overexpression without any gene 
amplification. However, it is still unknown why 
HER2 does not migrate to the cell membrane, as it 
should being a transmembrane receptor. Whether it is 
a simple matter of quantities, and whether this tran-
scriptional upregulation result in not enough HER2 
to migrate to the cell membrane is unknown. It is con-
troversial as the western blots from Kapitanovic et al 
and Osako et al exhibit a much denser signal when 
analyzing the cytoplasmic overexpressing cells, 
when compared to the membranous overexpress-
ing cells.18,45 However, the 12-fold higher mRNA 
expression in membranous HER2 overexpressing 
tumors compared to cytoplasmic overexpression as 
discovered by Half et al would support this theory. 
Perhaps there is an unknown HER2-transporter pro-
tein which is also regulated by the promoter-binding 
protein. Or perhaps the protein is in some way trun-
cated when being overexpressed at a transcriptional 
level. Other possibilities include there being an 
actual 155 kD cleavage product incapable of migrat-
ing to the membrane or an immune-evasive strategy 
by the tumor. One theory is based on the influence 
of the unfolded protein response (UPR). Upon cel-
lular stress, this response initially stimulates multi-
ple chaperone proteins in the endoplasmic reticulum 
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in order to increase the glycosylation and folding 
capacity of the endoplasmic reticulum, and induces 
apoptosis when this initial response is insufficient. 
UPR activation in breast cancer cells has been 
demonstrated.56 In normal, non-malignant cells there 
is a baseline expression of HER2, which leads to a 
HER2 on a cell membrane that cannot be detected 
by regular immunohistochemistry (Fig. 2A). A pos-
sible theory is that in the case of overexpression of 
the HER2-gene, there is a surplus of HER2 mRNA 
which, after being translated into protein, cannot be 
handled properly in the ER and thus leads to aberrant 
glycosylation or misfolding of the immature protein 
(Fig. 2C). In this case, either the Golgi apparatus is 
not capable of maturing the protein or the protein 
cannot be transported to the Golgi apparatus, both of 
which lead to accumulation of aberrant HER2 within 
the cytoplasm. This accumulation would trigger the 
UPR. The presence of an activated UPR will lead 
to an increase in properly glycosylated and folded 
protein, and the overexpression of HER2 by the cell 
at the membrane. However, for an unknown reason, 
gene amplification of HER2 in breast cancer leads 
to a more efficient UPR than HER2-overexpression 
in colorectal cancer (Fig. 2B). This difference in 
UPR could be influenced by other processes which 
affect cellular stress such as hypoxia, nutrient avail-
ability, treatment, or other genetic instabilities. This 
may lead to the situation that UPR in breast cancer is 











Figure 2. A schematic representation of the difference in HeR2 expression between multiple cell types. In a normal cell (A), a single copy of the HeR2-
gene is transcribed to low levels of mRNA, which is then translated to HeR2 which enters the endoplasmatic reticulum (eR). In the eR, HeR2 is processed 
(eg, glycosylated), and transported to the Golgi apparatus (GA). There it undergoes final processing before being transported to the membrane. In breast 
cancer (B), this process is basically identical except that gene amplification leads to higher mRNA and HER2 levels. The processing capacity of the ER is 
improved, most likely due to the unfolded protein response (UPR). In colorectal cancer however (c), there is no gene amplification, but gene expression 
is upregulated during transcription.
notes: The eR cannot keep up with the high amount of protein, therefore immature HeR2 cannot to be completely processed in the eR, and can-
not be transported to the GA and the cell membrane; instead incompletely folded HeR2 might be extracted from the eR via the eR associated deg-
radation pathway, deglycosylated into a 155–160 kDa protein prior to it accumulation and ultimately proteasomal degradation in the cytoplasm.58
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HER2, while in colorectal cancer the UPR fails to 
do so which leads to accumulation of misfolded and 
aberrantly glycosylated HER2. This unglycosylated 
form of HER2 might be identical to the p155 variant 
mentioned before.
conclusions
It is clear that most of the debate around HER2-
overexpression in colorectal cancer is due to differ-
ences in staining/scoring techniques. When splitting 
the results in membranous and cytoplasmic overex-
pression, a clear pattern appears with approximately 
5% of all patients having membranous overexpres-
sion, and about 30% of all patients having cytoplasmic 
overexpression. There is a strong correlation between 
genomic amplification and membranous overexpres-
sion, whereas no genomic amplification is observed 
in cases with cytoplasmic HER2 expression.23,26,54
With around 5% of all colorectal cancers overex-
pressing HER2 on their membrane, this would create a 
new treatment strategy with trastuzumab for approxi-
mately 60,000 patients worldwide per year. Unfortu-
nately, a clinical trial was ended due to a lack of patient 
accrual.57 A large, multicenter trial would be needed 
to include enough patients for sufficient analysis.
In contrast to membranous HER2 overexpres-
sion, a significant proportion of colorectal tumors 
(30%–50%) show cytoplasmic HER2 overexpres-
sion in most studies. The identity of cytoplasmic 
HER2 remains unclear, although there is some indi-
rect evidence that it is derived from the upregulation 
of promoter-binding proteins leading to an increase 
in HER2 production. Additionally, the prognostic 
value of cytoplasmic HER2 is still unclear. An exten-
sive study using standardized techniques on a large 
number of tumors is needed to elucidate this matter. 
If cytoplasmic HER2 has a pathophysiological role 
in colorectal cancer, intracellular HER2-targeting 
compounds, for example lapatinib, might be a new 
treatment option for the 30% of patients having cyto-
plasmic HER2 overexpression. This would impact 
about 360,000 patients per year; a clear breakthrough 
in the treatment of colorectal cancer.
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